Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2013, vol. 22, nr 5, September-October, p. 759–766

Publication type: review article

Language: English

The Therapeutic Effect of Probiotic Bacteria on Gastrointestinal Diseases

Rola probiotyków w profilaktyce i leczeniu chorób przewodu pokarmowego

Jolanta Sarowska1,A,B,C,D,E,F, Irena Choroszy-Król1,A,B,C,D,E,F, Bożena Regulska-Ilow2,A,B,C,D,E,F, Magdalena Frej-Mądrzak1,A,B,C,D,E,F, Agnieszka Jama-Kmiecik1,A,B,C,D,E,F

1 Department of Basic Sciences, Wroclaw Medical University, Poland

2 Department of Dietetics, Wroclaw Medical University, Poland

Abstract

The cause of many gastrointestinal diseases, such as irritable bowel syndrome, chronic inflammatory bowel disease: inflammatory and necrotizing enterocolitis or diarrhea: infectious, traveler’s diarrhea, and diarrhea caused by antibiotic treatment is an imbalance of intestinal microflora. Probiotics are live microorganisms, which administered in sufficient quantities, have beneficial health effects. The phenomenon of eating probiotic products started 100 years ago, when the first reports showed beneficial effects of probiotic bacteria on human health. Since then, probiotic preparations have become an essential element in the prevention and treatment of certain diseases. Currently, probiotics are of the utmost importance in supporting the treatment of gastrointestinal diseases and autoimmune disorders. Probiotic microorganisms are primarily lactic acid-producing bacteria of the general Lactobacillus, Bifidobacterium. Many studies have confirmed the beneficial effects of probiotics, particularly in the treatment of acute diarrhea. This applies in particular to diarrhea of viral etiology, especially in infants and young children.

Streszczenie

Przyczyną wielu chorób przewodu pokarmowego, takich jak np.: zespół jelita nadwrażliwego, przewlekłe choroby zapalne jelit – nieswoiste i martwicze zapalenie jelit, biegunki – infekcyjna, podróżnych, poantybiotykowa, są zaburzenia równowagi mikroflory jelitowej. Probiotyki to żywe drobnoustroje, które podawane w odpowiednich ilościach wywierają korzystny efekt zdrowotny. Zjawisko probiozy zaczęto wykorzystywać już 100 lat temu, gdy pojawiły się pierwsze doniesienia o korzystnym wpływie bakterii probiotycznych na zdrowie człowieka. Od tamtego czasu preparaty probiotyczne stały się istotnym elementem w profilaktyce i leczeniu niektórych chorób. Obecnie probiotyki mają największe znaczenie we wspomaganiu leczenia chorób układu pokarmowego oraz zaburzeń autoimmunologicznych. Do drobnoustrojów o działaniu probiotycznym należą przede wszystkim bakterie produkujące kwas mlekowy z rodzaju: Lactobacillus, Bifidobacterium. Wiele badań potwierdziło korzystne działanie probiotyków, przede wszystkim w leczeniu ostrej biegunki. Dotyczy to przede wszystkim biegunek o etiologii wirusowej, zwłaszcza u niemowląt i małych dzieci.

Key words

probiotics, gastrointestinal diseases.

Słowa kluczowe

probiotyki, choroby przewodu pokarmowego.

References (60)

  1. Neish AS: Microbes in gastrointestinal health and disease. Rev Bas Clin Gastroenterol 2009, 136, 65–80.
  2. Metchnikoff E: The prolongation of life. New York: G.P. Putnom & Sons 1907.
  3. Nissle A: Die antagonistische Behandlung chronischer Darmstorungen mit Colibakterien. Med Klin 1918, 2, 29–33.
  4. Vasiljevic T, Shah NP: Probiotics – from Metchnikoff to bioactives. Int Dairy J 2008, 18, 714–728.
  5. Vergin F: Antiund Probiotika. Hippokrates 1954, 25, 16–119.
  6. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada, April 30 and May 1, 2002.
  7. Madsen K, Jijon H, Yeung H: DNA from probiotic bacteria exerts anti-inflammatory actions on epithelial cells by inhibition of NFκB. Gastroenterol 2002, 122, Abstract 546.
  8. Rachmilewitz D, Karmeli F, Takabayashi K: Amelioration of experimental colitis by probiotics is due to the immunostimulatory effect of its DNA. Gastroenterol 2002, 122, Abstract T1004.
  9. Naidu AS, Bidlack WR, Clemens RA: Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr 1999, 39, 13–126.
  10. Moneta J, Libudzisz Z: Suitability of Lactobacillus strains as components of probiotics. [In:] Food Biotechnology. Vol. 17 Progress in Biotechnology, Elsevier Science B.V., Amsterdam, The Netherlandes 2000, 257–264.
  11. Schrezenmeir J, de Vrese M: Probiotics, prebiotics, and synbiotics – approaching a definition. Am J Clin Nutr 2001, 73, 361–364.
  12. Madaliński K, Szajewska H: Probiotics: mechanism of action, immunomodulation and potential use in gastrointestinal diseases. Zakażenia 2004, 5, 42–48.
  13. Czerwionka-Szaflarska M, Romańczuk B: Probiotics – which, whom, when? Przew Lek 2008, 1, 214–221.
  14. Servin AL: Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 2004, 28, 405–40.
  15. Elmer GW: Probiotics: “living drugs”. Am J Health Syst Pharm 2001, 58, 1101–1109.
  16. Ruszczyński M, Radzikowski A, Szajewska H: Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Alimentary Pharmacol Therap 2008, 28, 154–161.
  17. Alakomi HL, Skytta E, Saarela M, Mattila-Sandholm T, Latva-Kala K, Helander IM: Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol 2000, 66, 2001–2005.
  18. Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S: Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 2006, 281, 24449–24454.
  19. Wold AE: Immune effects of probiotics. Scand J Nutr 2001, 45, 76–85.
  20. PharmacoEconomics & Outcomes News: Recommendations for the use of probiotics have been released following the Advances in Clinical Use of Probiotics Workshop. 9 August 2008, Volume, Issue 559, 5, Guideline.
  21. Vandenplas Y, De Hert SG: Randomised clinical trial: the synbiotic food supplement probiotical vs. placebo for acute gastroenteritis in children. Aliment Pharmacol Ther 2011, 34, 862–867.
  22. Boyle RJ, Robins-Browne RM, Tang ML: Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006, 83, 1256–1264.
  23. Casburn-Jones AC, Farthing MJ: Management of infectious diarrhoea. Gut 2004, 53, 296–305.
  24. Guarino A, Albano F, Ashkenazi S, Gendrel D, Hoekstra JH, Shamir R, Szajewska H: European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008, 46, 619–621.
  25. Guandalini S: Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 2011, 149–153.
  26. Le Luyer B, Makhoul G, Duhamel JF: Étude multicentrique, contrôlée en double insu d’une formule adaptée enrichie en Saccharomyces boulardii dans le traitement des diarhées aiguës du nourisson. Archiv Pediatrie 2010, 17, 459–465.
  27. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF: Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004, CD003048.
  28. Corrêa N, Penna F, Lima F, Nicoli J, Péret Filho L: Treatment of acute diarrhea with Saccharomyces boulardii in infants: a double-blind, randomized, placebo controlled trial. J Clin Gastroenterol 2011, 149–153.
  29. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De VA, Albano F, Passariello A, De MG, et al.: Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007, 335, 340–345.
  30. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE: Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 2006, 6, 374–382.
  31. Szajewska H, Hoekstra JH, Sandhu B: Management of acute gastroenteritis in Europe and the impact of the new recommendations: a multicenter study. The Working Group on acute Diarrhoea of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2000, 30, 522–527.
  32. Szajewska H, Mrukowicz JZ: Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001, 33, 17–25.
  33. Szajewska H, Skorka A, Dylag M: Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007, 25, 257–264.
  34. Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D: Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007, 25, 871–881.
  35. Aggett PJ, Agostoni C, Axelsson I, Braegger C, Goulet O, Koletzko B, Michaelsen KF, Rigo J, Shamir R, Szajewska H, Turck D, Weaver LT: Probiotic bacteria in dietetic products for infants: A Commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2004, 38, 4, 365–374.
  36. Maldonaldo J, Lara-Villoslada F, Sierra S, Sempere L, Gomez M, Rodriguez JM, Boza J, Xaus J, Olivares M: Safety and tolerance of the human milk probiotic strain Lactobacillus salivarius CECT5713 in 6-month-old children. Nutrition 2010, 26, 1082–1087.
  37. Gascón J: Epidemiology, etiology and pathophysiology of traveler’s diarrhea. Digestion 2006, 73, 1, 102–108.
  38. Al-Abri SS, Beeching NJ, Nye FJ: Traveller’s diarrhoea. Lancet Infect Dis 2005, 5, 349–360.
  39. McFarland LV: Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis 2007, 5, 97–105.
  40. Szajewska H, Ruszczynski M, Radzikowski A: Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006, 149, 367–372.
  41. Ruszczynski M, Radzikowski A, Szajewska H: Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Alimentary Pharmacol Therap 2008, 28, 154–161.
  42. Hickson M, D’Souza AL, Muthu N: Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007, 335, 80.
  43. McFarland LV: Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006, 101, 812–822.
  44. Hickson M, D’Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ: Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomized double blind placebo controlled trial. BMJ 2007, 335, 80.
  45. Rohde CL, Bartolini V, Jones N: The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea. Nutr Clin Pract 2009, 24, 33–40.
  46. Lin HC, Su BH, Chen AC: Probiotics may reduce risk of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005, 115, 1–4.
  47. Deshpande G, Rao S, Patole S, Bulsara M: Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010, 125, 5, 921–930.
  48. Deshpande G, Rao S, Patole S: Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birth weight: a systemic review of randomized controlled trials. Lancet 2007, 369, 1614–1620.
  49. Mihatsch WA, Braegger CP, Decsi T: Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clinical Nutri 2012, 31, 1, 6–15.
  50. Fedorak RN: Probiotics in the management of ulcerative colitis. Gastroenterol Hepatol (NY) 2010, Nov, 6, 11, 688–690.
  51. Floch MH: Probiotic therapy for ulcerative colitis. J Clin Gastroenterol 2010, Apr, 44, 4, 237–238.
  52. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A: Effect of aprobiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009, 104, 437–443.
  53. Kruis W, Fric P, Pokrotnieks J: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53, 1617–1623.
  54. Shanahan F: Crohn’s disease. Lancet 2002, 359, 62–69.
  55. Prantera C: Probiotics for Crohn’s disease: what have we learned? Gut 2006, 55, 6, 757–759.
  56. Hedin C, Whelan K, Lindsay JO: Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007, 66, 307–315.
  57. McFarland LV, Dublin S: Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008, May, 7, 14, 17, 2650–2661.
  58. Sawant PD, Venkatramant J, Ducrotte P: Evaluation of Lactobacillus plantarum 299v Efficacy in IBS: Results of a Randomized Placebo-Controlled Trial in 200 Patients. Gastroenterol 2010, DDW.
  59. Kruis W, Chrubasik S, Boehm S: A double-blind placebocontrolled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012, 27, 467–474.
  60. Rogers NJ, Mousa SA: The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome. J Altern Complement Med 2012, Feb, 18, 2, 112–119.
© Wroclaw Medical University